Evidence map›Paper›PMID 31138227›Full record

ArticleJournal of neuroinflammation2019

Augmented β2-adrenergic signaling dampens the neuroinflammatory response following ischemic stroke and increases stroke size.

Kendra J Lechtenberg, Scott T Meyer, Janelle B Doyle, Todd C Peterson, Marion S Buckwalter

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Neutrophil βBritish journal of pharmacology · 2023
    Article
  18. Article
  19. Article
  20. Single cell profiling of CD45Journal of neuroinflammation · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kendra J LechtenbergDepartment of Neurology and Neurological Sciences, Stanford School of Medicine, Palo Alto, Stanford, CA, 94305, USA.
Scott T MeyerDepartment of Neurology and Neurological Sciences, Stanford School of Medicine, Palo Alto, Stanford, CA, 94305, USA.
Janelle B DoyleDepartment of Neurology and Neurological Sciences, Stanford School of Medicine, Palo Alto, Stanford, CA, 94305, USA.
Todd C PetersonDepartment of Neurology and Neurological Sciences, Stanford School of Medicine, Palo Alto, Stanford, CA, 94305, USA.
Marion S BuckwalterDepartment of Neurology and Neurological Sciences, Stanford School of Medicine, Palo Alto, Stanford, CA, 94305, USA. marion.buckwalter@stanford.edu.ORCID http://orcid.org/0000-0003-2807-2447
Stanford Medicine · US

Funding

Training Program in Basic NeuroscienceT32MH020016 · NIMH · STANFORD UNIVERSITY · PI Justin L Gardner, Merritt C Maduke · 1997 to 2026
$16.2M
TGFbeta signaling, reactive astrogliosis and function after strokeR01NS067132 · NINDS · STANFORD UNIVERSITY · PI BUCKWALTER, MARION S · 2011 to 2015
$1.9M
Spleen glia in autonomic regulation of immunityR21NS098716 · NINDS · STANFORD UNIVERSITY · PI BUCKWALTER, MARION S · 2016 to 2017
$454k
National Science Foundation DGE-114747NIH HHS R21 NS098716NIH HHS RO1 NS067132NIMH NIH HHS T32 MH020016NINDS NIH HHS R01 NS067132NINDS NIH HHS R21 NS098716
6 · The paper itself

Abstract

backgroundIschemic stroke provokes a neuroinflammatory response and simultaneously promotes release of epinephrine and norepinephrine by the sympathetic nervous system. This increased sympathetic outflow can act on β2-adrenergic receptors expressed by immune cells such as brain-resident microglia and monocyte-derived macrophages (MDMs), but the effect on post-stroke neuroinflammation is unknown. Thus, we investigated how changes in β2-adrenergic signaling after stroke onset influence the microglia/MDM stroke response, and the specific importance of microglia/MDM β2-adrenergic receptors to post-stroke neuroinflammation.

methodsTo investigate the effects of β2-adrenergic receptor manipulation on post-stroke neuroinflammation, we administered the β2-adrenergic receptor agonist clenbuterol to mice 3 h after the onset of photothrombotic stroke. We immunostained to quantify microglia/MDM numbers and proliferation and to assess morphology and activation 3 days later. We assessed stroke outcomes by measuring infarct volume and functional motor recovery and analyzed gene expression levels of neuroinflammatory molecules. Finally, we evaluated changes in cytokine expression and microglia/MDM response in brains of mice with selective knockout of the β2-adrenergic receptor from microglia and monocyte-lineage cells.

resultsWe report that clenbuterol treatment after stroke onset causes enlarged microglia/MDMs and impairs their proliferation, resulting in reduced numbers of these cells in the peri-infarct cortex by 1.7-fold at 3 days after stroke. These changes in microglia/MDMs were associated with increased infarct volume in clenbuterol-treated animals. In mice that had the β2-adrenergic receptor specifically knocked out of microglia/MDMs, there was no change in morphology or numbers of these cells after stroke. However, knockdown of β2-adrenergic receptors in microglia and MDMs resulted in increased expression of TNFα and IL-10 in peri-infarct tissue, while stimulation of β2-adrenergic receptors with clenbuterol had the opposite effect, suppressing TNFα and IL-10 expression.

conclusionsWe identified β2-adrenergic receptor signaling as an important regulator of the neuroimmune response after ischemic stroke. Increased β2-adrenergic signaling after stroke onset generally suppressed the microglia/MDM response, reducing upregulation of both pro- and anti-inflammatory cytokines, and increasing stroke size. In contrast, diminished β2-adrenergic signaling in microglia/MDMs augmented both pro- and anti-inflammatory cytokine expression after stroke. The β2-adrenergic receptor may therefore present a therapeutic target for improving the post-stroke neuroinflammatory and repair process.

Indexed as

Adrenergic beta-AgonistsAnimalsBrain IschemiaInflammation MediatorsMaleMiceMice, Inbred C57BLMice, TransgenicReceptors, Adrenergic, beta-2Signal TransductionStrokeAdrenergic beta-AgonistsInflammation MediatorsReceptors, Adrenergic, beta-2AutonomicBeta2-adrenergic receptorInfarctIschemic strokeMacrophageMicrogliaNeuroinflammationSympatheticTNFα

Identifiers

PMID31138227
PMCPMC6540436
OpenAlexW2947585807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.